# Effect of Remazolam Besylate Combined With Remifentanil Analgesic Sedation on the Prognosis of Patients With Sepsis

> **NCT06731088** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **First Affiliated Hospital of Ningbo University** · enrollment: 100 (estimated)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** Midazolam
- **DRUG:** Remazolam besylate

## Key facts

- **NCT ID:** NCT06731088
- **Lead sponsor:** First Affiliated Hospital of Ningbo University
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-01-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06731088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06731088, "Effect of Remazolam Besylate Combined With Remifentanil Analgesic Sedation on the Prognosis of Patients With Sepsis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06731088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*